Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mefloquine Hydrochloride

FDA-approved product (tablet, oral), marketed as Lariam, Mefloquine Hydrochloride.

Registered studies
8
Lab records
2
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Mefloquine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria
  • Plasmodium falciparum malaria
  • Plasmodium vivax malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Methanolquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BC02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis81.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

8registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Mefloquine Hydrochloride in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mefloquine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)

    NCT03939104 · start 2021-06-30

    Registered record
    Registry ID
    NCT03939104
    Conditions
    Plasmodium Falciparum Malaria (Uncomplicated)
    Interventions
    Artemether-lumefantrine+amodiaquine; Artemether-lumefantrine+placebo; Artesunate-mefloquine+piperaquine; Artesunate-mefloquine+placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2023-01-28
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Uncomplicated)
    InterventionArtemether-lumefantrine+amodiaquine; Artemether-lumefantrine+placebo; Artesunate-mefloquine+piperaquine; Artesunate-mefloquine+placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial

    NCT04847661 · start 2021-03-28

    Registered record
    Registry ID
    NCT04847661
    Conditions
    Covid19
    Interventions
    Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-03-28
    Completion
    2022-06-30
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionMefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

    NCT03923725 · start 2020-09-01

    Registered record
    Registry ID
    NCT03923725
    Conditions
    Plasmodium Falciparum Malaria (Uncomplicated)
    Interventions
    Artemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO); Artesunate-mefloquine+piperaquine (AS-MQ+PPQ); Artesunate-mefloquine+placebo (AS-MQ+PBO)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-01
    Completion
    2024-03-15
    Enrolment
    2,583

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Uncomplicated)
    InterventionArtemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO); Artesunate-mefloquine+piperaquine (AS-MQ+PPQ); Artesunate-mefloquine+placebo (AS-MQ+PBO)
    PhasePhase 3
    Registry statusCompleted

  • A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

    NCT02453308 · start 2015-08

    Registered record
    Registry ID
    NCT02453308
    Conditions
    Malaria, Falciparum
    Interventions
    ACT; TACT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-08
    Completion
    2018-03
    Enrolment
    1,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionACT; TACT
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

    NCT01430351 · start 2011-09-14

    Registered record
    Registry ID
    NCT01430351
    Conditions
    Glioblastoma; Gliosarcoma; Supratentorial Glioblastoma
    Interventions
    Mefloquine; Memantine Hydrochloride; Metformin Hydrochloride; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-09-14
    Completion
    2025-02-02
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Gliosarcoma; Supratentorial Glioblastoma
    InterventionMefloquine; Memantine Hydrochloride; Metformin Hydrochloride; Temozolomide
    PhasePhase 1
    Registry statusTerminated

  • Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

    NCT00852423 · start 2010-06

    Registered record
    Registry ID
    NCT00852423
    Conditions
    Malaria in Pregnancy
    Interventions
    Dihydroartemisinin-piperaquine; Artesunate-mefloquine; Artesunate-amodiaquine; Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2015-04
    Enrolment
    3,428

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria in Pregnancy
    InterventionDihydroartemisinin-piperaquine; Artesunate-mefloquine; Artesunate-amodiaquine; Artemether-lumefantrine
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria

    NCT00902811 · start 2008-12

    Registered record
    Registry ID
    NCT00902811
    Conditions
    Uncomplicated Falciparum Malaria
    Interventions
    AM(FDC); AM(LT); AL; DP; AA(FDC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-12
    Completion
    2009-12
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Falciparum Malaria
    InterventionAM(FDC); AM(LT); AL; DP +1 more
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function

    NCT00444106 · start 2007-05

    Registered record
    Registry ID
    NCT00444106
    Conditions
    Malaria; Falciparum
    Interventions
    Artesunate-mefloquine; Atovaquone-proguanil; Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2008-11
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Falciparum
    InterventionArtesunate-mefloquine; Atovaquone-proguanil; Artemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted